Susanna Giordano

Susanna Giordano

Auto-generated profile, based on publicly available information

Susanna Giordano

S.C. Farmacia Ospedaliera, A.O.U. Città Della Salute e Della Scienza di Torino, 10126 Turin, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Virus Research
Verified
Journal Article
Closed access
FCFrancesco Cattel
Francesco Cattel
SGSusanna Giordano
Susanna Giordano
CBCecilia Bertiond
Cecilia Bertiond
TLTommaso Lupia
Tommaso Lupia
SCSilvia Corcione
Silvia Corcione
FRFrancesco Giuseppe De Rosa
Francesco Giuseppe De Rosa

20 May 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
Nour ShbakloNour Shbaklo
Nour Shbaklo
Silvia CorcioneSilvia Corcione
Silvia Corcione
CVCostanza Vicentini
Costanza Vicentini
SGSusanna Giordano
Susanna Giordano
DFDenise Fiorentino
Denise Fiorentino
FRFrancesco Giuseppe De Rosa
Francesco Giuseppe De Rosa
The pandemic caused by the COVID-19 virus has required major adjustments to healthcare systems, especially to infection control and antimicrobial stewardship. The objective of this study was to describe the incidence of multidrug-resistant (MDR) hospital-acquired infections (HAIs) and antibiotic consumption during the three waves of COVID-19 and to compare it to the period before the outbreak at Molinette Hospital, located in the City of Health and Sciences, a 1200-bed teaching hospital with surgical, medical, and intensive care units. We demonstrated an increase in MDR infections: particularly in K. pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), A. baumannii, and MRSA. Fluoroquinolone use showed a significant increasing trend in the pre-COVID period but saw a significant reduction in the COVID period. The use of fourth- and fifth-generation cephalosporins and piperacillin–tazobactam increased at the beginning of the COVID period. Our findings support the need for restoring stewardship and infection control practices, specifically source control, hygiene, and management of invasive devices. In addition, our data reveal the need for improved microbiological diagnosis to guide appropriate treatment and prompt infection control during pandemics. Despite the infection control practices in place during the COVID-19 pandemic, invasive procedures in critically ill patients and poor source control still increase the risk of HAIs caused by MDR organisms.

1 January 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
Franco DosioFranco Dosio
Franco Dosio
Barbara StellaBarbara Stella
Barbara Stella
AFAnnalisa Ferrero
Annalisa Ferrero
CGClaudio Garino
Claudio Garino
DZDaniele Zonari
Daniele Zonari
GRGobetto Roberto
Gobetto Roberto
Transition metal complexes provide a promising avenue for designing new therapeutic and diagnostic agents. In particular, ruthenium(II) polypyridyl complexes are useful for studying cellular uptake, due to their easy synthesis and unique photophysical properties. Dyes are frequently combined with material substrates to modulate their properties, enhance stability, reduce toxicity, and improve delivery. A novel Ru polypyridyl complex linked to a derivative of the natural lipid squalene (Ru-BIPPBI-hx-SQ) is described. Using the solvent displacement method, Ru-BIPPBI-hx-SQ easily self-assembles into nanosized aggregates in aqueous solution, as characterized by dynamic light scattering. The nanoassemblies exhibit long-lived and intense luminescence. Preliminary biological assessment showed them to be non-toxic; they are efficiently and rapidly transported across the cell membrane without requiring its permeabilization. Ru-labeled nanoassemblies are likely to be significant cellular-imaging tools, probing cellular events at very low concentrations. Moreover co-nanoassembly, with drug-derivatives based on squalenoylation technology, including gemcitabine and paclitaxel, has given interesting preliminary results.

11 November 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
LCLuigi Cattel
Luigi Cattel
SGSusanna Giordano
Susanna Giordano
STSara Traina
Sara Traina
TLTommaso Lupia
Tommaso Lupia
SCSilvia Corcione
Silvia Corcione
FCFrancesco Cattel
Francesco Cattel
Severe acute respiratory syndrome coronavirus 2 is associated with a severe respiratory disease in China, that rapidly spread across continents. Since the beginning of the pandemic, available data suggested the asymptomatic transmission and patients were treated with specific drugs with efficacy and safety data not always satisfactory. The aim of this review is to describe the vaccines developed by three companies, Pfizer‐BioNTech, Moderna, and University of Oxford/AstraZeneca, in terms of both technological and pharmaceutical formulation, safety, efficacy, and immunogenicity. A critical analysis of Phases 1, 2, and 3 clinical trial results available was conducted, comparing the three vaccine candidates, underlining their similarities and differences. All candidates showed consistent efficacy and tolerability; although some differences can be noted, such as their technological formulation, temperature storage, which will be related to logistics and costs. Further studies will be necessary to evaluate long‐term effects and to assess the vaccine safety and efficacy in the general population.